Phospho-HDAC4/HDAC5/HDAC9 (Ser246/259/220) Antibody

What are HDAC4, HDAC5, and HDAC9, and why are their phosphorylated forms important?

HDAC4, HDAC5, and HDAC9 belong to the class IIa histone deacetylase family, which play critical roles in transcriptional regulation through chromatin remodeling. These proteins function by deacetylating histones, leading to chromatin condensation and transcriptional silencing. The phosphorylation of specific serine residues (Ser246 in HDAC4, Ser259 in HDAC5, and Ser220 in HDAC9) creates docking sites for 14-3-3 chaperone proteins, which promote their translocation from the nucleus to the cytoplasm. This subcellular redistribution is a major regulatory mechanism that controls their corepressor functions and impacts downstream gene expression .

The phosphorylation status of these residues serves as a molecular switch that determines whether these HDACs can exert their transcriptional repressive effects in the nucleus or are sequestered in the cytoplasm. This regulation is particularly important in various physiological and pathological processes, including cancer development, where HDAC4 has been identified as a multitasking platform driving tumorigenic mechanisms .

What experimental applications are validated for Phospho-HDAC4/HDAC5/HDAC9 (Ser246/259/220) antibodies?

Phospho-HDAC4/HDAC5/HDAC9 (Ser246/259/220) antibodies have been validated for several key experimental applications in molecular and cellular biology research:

• Western Blot (WB): For detecting the phosphorylated forms of HDAC4, HDAC5, and HDAC9 in protein lysates .

• Immunohistochemistry (IHC): For visualizing the localization and expression of phosphorylated HDACs in tissue sections .

• Immunohistochemistry-Paraffin (IHC-P): Specifically optimized for detection in paraffin-embedded tissue samples .

These antibodies have been tested for reactivity with human samples, making them valuable tools for translational research studying HDAC regulation in human tissues and cells . When designing experiments, researchers should validate specificity in their particular experimental systems, as cross-reactivity profiles may vary between different antibody sources.

Which kinases are responsible for phosphorylating Ser246/259/220 in HDAC4/5/9?

Multiple kinases have been identified that phosphorylate the key serine residues in HDAC4, HDAC5, and HDAC9. These represent important convergence points for diverse signaling pathways:

• Calcium/calmodulin-dependent kinases (CaMKs):

  • CaMKI preferentially phosphorylates S246 in HDAC4

  • CaMKII phosphorylates residues S467 and S632 by binding to a unique docking site centered on Arg601 in HDAC4

  • CaMKIV can phosphorylate the same serines and promote nuclear export independent of 14-3-3 binding

• Protein Kinase D1 (PKD1): Phosphorylates residues S246 and S467 in HDAC4, promoting nuclear export and cytoplasmic retention

• MARK/Par-1 kinases (including EMK and C-TAK1): Control HDAC4 localization by phosphorylating S246, facilitating subsequent phosphorylation of S467 and S632 by other kinases

• Salt-inducible kinases (SIKs):

  • SIK3 phosphorylates HDAC4 during food intake in response to insulin

  • SIK2 mediates phosphorylation in mouse hepatocytes in response to insulin

  • SIK1 phosphorylates class IIa HDACs in muscle cells

• AMP-activated protein kinase (AMPK): Phosphorylates HDAC4 and HDAC5 to promote nuclear exclusion and epigenomic resetting

This complex network of kinases allows for context-specific regulation of HDAC4/5/9 in response to diverse physiological stimuli and signaling events.

How does phosphorylation at Ser246/259/220 regulate HDAC4/5/9 function?

Phosphorylation at Ser246/259/220 serves as a sophisticated regulatory mechanism that controls multiple aspects of HDAC4/5/9 function:

• Subcellular localization: Phosphorylation at these sites creates binding motifs for 14-3-3 chaperone proteins, which mask the nuclear localization signal (NLS) and promote translocation from the nucleus to the cytoplasm. This prevents the HDACs from associating with nuclear transcription factors like MEF2 and thereby relieves transcriptional repression .

• Transcriptional activity: When phosphorylated and exported to the cytoplasm, these HDACs can no longer repress target genes. The phosphorylation specifically enhances the transcriptional activity of MEF2 by preventing HDAC-mediated repression .

• Protein complex formation: Phosphorylation affects the ability of these HDACs to form protein complexes with other transcriptional regulators. For example, Aurora B-mediated phosphorylation of serine 265 in HDAC4 results in decreased association with HDAC3, impairing its repressive function .

• Protein stability: Some phosphorylation events, particularly those mediated by GSK3β at S298 and S302 in HDAC4, provide signals for poly-ubiquitylation and subsequent proteasomal degradation .

This phosphorylation-dependent regulation is reversible through the action of protein phosphatase 2A (PP2A), which dephosphorylates these sites, enabling nuclear import and restoration of transcriptional repression functions .

What are the optimal protocols for using Phospho-HDAC4/5/9 antibodies in Western blotting?

When using Phospho-HDAC4/5/9 (Ser246/259/220) antibodies for Western blotting, researchers should consider the following optimized protocol:

• Sample preparation:

  • Harvest cells during active signaling periods when phosphorylation is expected

  • Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, and β-glycerophosphate) in lysis buffers to preserve phosphorylation status

  • Use RIPA or NP-40 based buffers for efficient extraction of nuclear and cytoplasmic proteins

• Gel electrophoresis:

  • Use 7-8% SDS-PAGE gels for optimal resolution of HDAC4 (~140 kDa), HDAC5 (~122 kDa), and HDAC9 (~160 kDa)

  • Include phosphorylated protein standards as positive controls

• Transfer and blocking:

  • Transfer to PVDF membranes (rather than nitrocellulose) for better retention of phospho-proteins

  • Block with 5% BSA in TBST (not milk, which contains phosphatases)

• Antibody incubation:

  • Dilute primary antibody according to manufacturer recommendations (typically 1:1000)

  • Incubate overnight at 4°C with gentle agitation

  • Use phospho-specific secondary antibodies with enhanced sensitivity

• Controls and validation:

  • Include phosphatase-treated samples as negative controls

  • Use stimulated samples (e.g., calcium ionophore treatment to activate CaMK) as positive controls

  • Consider using single-knockout controls for specificity validation

This protocol should be optimized for specific experimental conditions and antibody sources to ensure reproducible and reliable results.

How should researchers design experiments to study HDAC4/5/9 phosphorylation dynamics?

To effectively study the dynamics of HDAC4/5/9 phosphorylation, researchers should implement a comprehensive experimental design that captures the temporal and spatial aspects of these modifications:

• Time-course experiments:

  • Establish baseline phosphorylation levels in resting cells

  • Treat cells with relevant stimuli (e.g., calcium ionophores for CaMK activation, insulin for SIK activation)

  • Collect samples at multiple time points (5 min, 15 min, 30 min, 1 hr, 2 hr, 4 hr)

  • Analyze by Western blotting with phospho-specific antibodies to track phosphorylation kinetics

• Subcellular fractionation:

  • Separate nuclear and cytoplasmic fractions to monitor translocation

  • Confirm fractionation quality with compartment-specific markers (e.g., Lamin B for nucleus, GAPDH for cytoplasm)

  • Analyze phosphorylation status in each compartment to correlate with localization

• Phosphorylation site mutants:

  • Generate S246A/S259A/S220A (phospho-null) mutants

  • Generate S246E/S259E/S220E (phospho-mimetic) mutants

  • Express in relevant cell lines to study functional consequences

• Kinase inhibitor studies:

  • Use specific inhibitors for relevant kinases (e.g., KN-93 for CaMK, YKL-05-099 for SIK3)

  • Monitor changes in phosphorylation and localization

  • Confirm with genetic approaches (siRNA/shRNA) to rule out off-target effects

• Live cell imaging:

  • Create phospho-sensor fusion proteins that change conformation or FRET signal upon phosphorylation

  • Monitor real-time changes in phosphorylation in response to stimuli

This multifaceted approach allows researchers to comprehensively characterize the signals that regulate HDAC4/5/9 phosphorylation and the resulting functional outcomes in various physiological and pathological contexts.

How can Phospho-HDAC4/5/9 antibodies be used to study cancer mechanisms?

Phospho-HDAC4/5/9 antibodies serve as valuable tools for investigating cancer mechanisms through several sophisticated approaches:

• Tumor microenvironment signaling:

  • HDAC4 is subject to microenvironment-dependent regulation through various PTMs including phosphorylation

  • Researchers can use these antibodies to profile how tumor microenvironment signals influence HDAC phosphorylation status

  • This helps elucidate how external cues lead to epigenetic reprogramming in cancer cells

• Epigenetic profiling in cancer progression:

  • Combine phospho-HDAC immunodetection with ChIP-seq to identify genomic regions affected by HDAC4/5/9 regulation

  • Correlate phosphorylation status with activating histone modifications (H3K4me3, H3K9ac, H3K27ac) and repressing modifications (H3K9me2, H3K27me3)

  • Map how HDAC phosphorylation status affects genome-wide epigenetic landscapes during cancer evolution

• Therapeutic resistance mechanisms:

  • In acute myeloid leukemia (AML), MEF2C acts as an oncogene that sustains cancer aggressiveness and chemoresistance

  • Phosphorylation of HDAC4 through SIK3 disrupts its ability to complex with MEF2C at enhancer sites

  • Researchers can track phosphorylation status to understand therapy response mechanisms

• Drug development and validation:

  • Screen compounds that modulate HDAC phosphorylation (e.g., SIK3 inhibitor YKL-05-099)

  • Use phospho-specific antibodies to monitor target engagement and pathway modulation

  • HDAC4 phosphorylation status can serve as a pharmacodynamic biomarker in preclinical models

• Context-specific cancer functions:

  • HDAC4 can exhibit both tumor-suppressive and oncogenic functions depending on cancer type

  • Phosphorylation status tracking helps determine which function predominates in specific contexts

  • This reveals potential customized targeting strategies for different cancer types

By employing these approaches, researchers can gain deeper insights into how HDAC4/5/9 phosphorylation contributes to cancer development and identify novel therapeutic vulnerabilities.

What is the relationship between HDAC4/5/9 phosphorylation and transcriptional regulation?

The relationship between HDAC4/5/9 phosphorylation and transcriptional regulation represents a sophisticated molecular switch that controls gene expression programs:

• Mechanism of transcriptional repression:

  • Unphosphorylated HDAC4/5/9 localize to the nucleus where they act as scaffolding proteins

  • They recruit enzymatically active partners including histone methyltransferases and class I HDACs

  • This multi-protein complex is directed to genomic locations specified by transcription factors like MEF2

  • The result is histone deacetylation followed by repressive modifications (H3K9me2, H3K27me3) that condense chromatin and prevent transcription factor binding

• Phosphorylation-dependent derepression:

  • Phosphorylation at Ser246/259/220 creates binding sites for 14-3-3 proteins

  • 14-3-3 binding masks the nuclear localization signal, causing nuclear export

  • This disrupts HDAC4/5/9 interaction with nuclear partners and relieves transcriptional repression

  • Target genes, particularly those regulated by MEF2, become activated

• Genome-wide consequences:

  • Genetic deletion of HDAC4 in mouse ventricular myocytes led to whole-epigenome activation

  • Increases in activating histone modifications (H3K4me3, H3K9ac, H3K27ac)

  • Decreases in repressing modifications (H3K9me2, H3K27me3)

  • ChIP-seq analysis revealed overrepresentation of MEF2 binding sites in upregulated regions

• Context-specific transcriptional programs:

  • In muscle cells, phosphorylation and nuclear export of HDAC4/5/9 permits MEF2-dependent transcription of muscle-specific genes

  • In leukemia cells, phosphorylation through SIK3 disrupts HDAC4-MEF2C complexes at enhancers, affecting H3K27 acetylation and regulating cell proliferation genes

• Integration with metabolic sensing:

  • During food intake, HDAC4 is phosphorylated and sequestered in the cytoplasm by SIK3 (upregulated by insulin)

  • During fasting, SIK3 is inactivated, leading to dephosphorylation and nuclear translocation of HDAC4

  • This couples metabolic status to specific transcriptional programs

This intricate relationship demonstrates how HDAC4/5/9 phosphorylation serves as a critical nexus connecting diverse signaling pathways to specific transcriptional outcomes, with important implications for development, homeostasis, and disease.

How can researchers distinguish between phosphorylation of HDAC4, HDAC5, and HDAC9 in experimental samples?

Distinguishing between phosphorylation of HDAC4, HDAC5, and HDAC9 requires careful experimental design and specialized techniques:

• Molecular weight differentiation:

  • In Western blot analysis, the three proteins have distinct molecular weights (HDAC4: ~140 kDa, HDAC5: ~122 kDa, HDAC9: ~160 kDa)

  • Use high-percentage gels (6-7%) with extended running times for better separation

  • Include molecular weight markers and loading controls with similar sizes for accurate identification

• Isoform-specific antibodies:

  • Complement phospho-specific antibodies with total protein antibodies against each specific HDAC

  • Perform sequential or parallel blotting with both phospho-specific and isoform-specific antibodies

  • Use specific antibodies against unique regions of each HDAC that are not conserved across family members

• Genetic approaches:

  • Employ siRNA/shRNA knockdown of individual HDACs followed by phospho-antibody detection

  • Generate cell lines with individual HDAC knockout using CRISPR-Cas9 technology

  • The signal that disappears in a specific knockout line corresponds to that HDAC

• Mass spectrometry:

  • Use phospho-proteomics approaches for definitive identification

  • Immunoprecipitate with phospho-antibody followed by mass spectrometry

  • Identify HDAC-specific peptides containing the phosphorylated residues

  • Mass spectrometry has revealed that HDAC5 alone has at least 17 in vivo phosphorylation sites, suggesting similar complexity in HDAC4 and HDAC9

• Expression systems:

  • Express tagged versions (HA, FLAG, etc.) of individual HDACs in cells

  • Analyze phosphorylation status using both tag antibodies and phospho-specific antibodies

  • This allows definitive correlation between specific HDAC isoforms and their phosphorylation status

These approaches can be combined for comprehensive analysis of HDAC4/5/9 phosphorylation in complex biological samples, enabling researchers to determine which specific family member is phosphorylated under various experimental conditions.

What are common pitfalls when working with phospho-specific antibodies and how can they be addressed?

Working with phospho-specific antibodies presents several challenges that researchers should anticipate and address:

• Loss of phosphorylation during sample preparation:

  • Problem: Phosphatases in cell/tissue lysates can rapidly dephosphorylate target proteins

  • Solution: Use comprehensive phosphatase inhibitor cocktails containing sodium orthovanadate, sodium fluoride, β-glycerophosphate, and calyculin A

  • Approach: Prepare samples on ice and process quickly to minimize phosphatase activity

• Specificity concerns:

  • Problem: Cross-reactivity with similar phosphorylation motifs on other proteins

  • Solution: Validate specificity using phosphorylation site mutants and/or HDAC4/5/9 knockout samples

  • Approach: Perform peptide competition assays with phosphorylated and non-phosphorylated peptides

• Sensitivity limitations:

  • Problem: Low abundance of phosphorylated forms may be difficult to detect

  • Solution: Enrich phosphorylated proteins using phospho-protein enrichment kits or immunoprecipitation

  • Approach: Use signal amplification systems such as HRP-conjugated polymers or tyramide signal amplification

• Dynamic range limitations:

  • Problem: Narrow dynamic range may not capture the full spectrum of phosphorylation changes

  • Solution: Use quantitative approaches like fluorescence-based Western blotting

  • Approach: Create standard curves with known quantities of phosphorylated recombinant proteins

• Context-dependent phosphorylation:

  • Problem: Phosphorylation status may change rapidly depending on cellular conditions

  • Solution: Perform careful time-course experiments with appropriate positive controls

  • Approach: Use kinase activators (e.g., ionomycin for CaMK) and inhibitors as controls

• Batch-to-batch variability:

  • Problem: Different antibody lots may show variable specificity and sensitivity

  • Solution: Validate each new antibody lot against previous lots using standard samples

  • Approach: Maintain frozen aliquots of control samples for consistent validation

By anticipating these common pitfalls and implementing appropriate solutions, researchers can enhance the reliability and reproducibility of experiments using Phospho-HDAC4/5/9 antibodies.

How might single-cell analysis techniques enhance our understanding of HDAC4/5/9 phosphorylation heterogeneity?

Single-cell analysis techniques offer unprecedented opportunities to understand the heterogeneity of HDAC4/5/9 phosphorylation across individual cells:

• Single-cell phospho-proteomics:

  • Enables measurement of phosphorylation states of multiple proteins simultaneously in individual cells

  • Reveals cell-to-cell variability in phosphorylation that may be masked in bulk analyses

  • Can identify rare cell populations with distinct HDAC phosphorylation patterns

• Mass cytometry (CyTOF) applications:

  • Development of metal-conjugated phospho-HDAC4/5/9 antibodies for mass cytometry

  • Integration with other phospho-protein markers and cell identity markers

  • Creation of high-dimensional phosphorylation landscapes at single-cell resolution

• Live-cell imaging of phosphorylation dynamics:

  • Engineered FRET-based biosensors for real-time monitoring of HDAC4/5/9 phosphorylation

  • Visualization of phosphorylation/dephosphorylation cycles in individual cells

  • Correlation with nuclear-cytoplasmic shuttling and transcriptional outputs

• Spatial transcriptomics integration:

  • Combination of phospho-HDAC immunofluorescence with spatial transcriptomics

  • Correlation between phosphorylation status and local gene expression patterns

  • Mapping of spatial phosphorylation gradients in tissues and their functional consequences

• Single-cell multi-omics approaches:

  • Integrated analysis of phospho-proteome, transcriptome, and epigenome in the same cell

  • Establishment of causal relationships between HDAC phosphorylation, chromatin modifications, and gene expression

  • Reconstruction of single-cell regulatory networks centered on HDAC4/5/9 phosphorylation

These advanced techniques will help resolve fundamental questions about the temporal dynamics, spatial distribution, and functional heterogeneity of HDAC4/5/9 phosphorylation in complex biological systems such as developing tissues, tumors, and neuronal networks.

What are the emerging therapeutic approaches targeting HDAC4/5/9 phosphorylation in disease contexts?

Several innovative therapeutic approaches targeting HDAC4/5/9 phosphorylation are emerging in various disease contexts:

• SIK inhibitors in cancer therapy:

  • Small molecule inhibitors like YKL-05-099 target SIK3, which phosphorylates HDAC4/5/9

  • In acute myeloid leukemia models, SIK3 inhibition reduced proliferation of leukemia cells and prolonged survival in mouse models (MLL-AF9 translocation)

  • This approach increases the nuclear pool of repressive-competent HDAC4, inhibiting cancer-promoting MEF2C activity

  • Considerations include potential off-target effects and context-dependent responses, as SIKs may act as tumor suppressors in some contexts

• Targeting phosphorylation-dependent protein-protein interactions:

  • Development of compounds that disrupt 14-3-3 binding to phosphorylated HDAC4/5/9

  • This approach could modulate nuclear-cytoplasmic shuttling without directly affecting phosphorylation

  • Potential for increased specificity compared to kinase inhibitors

• Phosphatase activators:

  • Compounds that enhance PP2A activity to promote dephosphorylation of HDAC4/5/9

  • PP2A activation could increase nuclear retention and repressive function

  • This approach may be valuable in contexts where HDAC nuclear function is beneficial

• Engineered phosphorylation site-specific degraders:

  • Proteolysis-targeting chimeras (PROTACs) designed to recognize phosphorylated forms of HDAC4/5/9

  • These could selectively degrade phosphorylated or unphosphorylated populations

  • Allows for nuanced manipulation of HDAC4/5/9 pools with different activities

• Combination with metabolism-targeting agents:

  • AMPK activators like metformin influence HDAC4/5/9 phosphorylation

  • Synergistic approaches combining metabolic modulation with direct HDAC targeting

  • This strategy leverages the integration of metabolic sensing and HDAC phosphorylation

These emerging approaches highlight the therapeutic potential of targeting HDAC4/5/9 phosphorylation, but careful consideration of context-specific effects is essential. The dual roles of these HDACs as both potential oncogenes and tumor suppressors depending on cellular context necessitates precision medicine approaches tailored to specific disease settings .